Nucleic acid drugs, also known as nucleic acid-based therapeutics, are a class of pharmaceuticals designed to treat various diseases by targeting specific genes or genetic processes within the human body. They are distinct from traditional small molecule drugs and instead rely on nucleic acids, which are the building blocks of genetic information. Nucleic acid drugs encompass various types of pharmaceuticals that use nucleic acids, such as DNA or RNA, as their active components to target specific genes or genetic processes.
The global Nucleic Acid and Oligonucleotide Drugs market size is projected to grow from US$ 12670 million in 2024 to US$ 15900 million in 2030; it is expected to grow at a CAGR of 3.9% from 2024 to 2030.
The 鈥淣ucleic Acid and Oligonucleotide Drugs Industry Forecast鈥� looks at past sales and reviews total world Nucleic Acid and Oligonucleotide Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Nucleic Acid and Oligonucleotide Drugs sales for 2023 through 2029. With Nucleic Acid and Oligonucleotide Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nucleic Acid and Oligonucleotide Drugs industry.
This Insight Report provides a comprehensive analysis of the global Nucleic Acid and Oligonucleotide Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Nucleic Acid and Oligonucleotide Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Nucleic Acid and Oligonucleotide Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nucleic Acid and Oligonucleotide Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nucleic Acid and Oligonucleotide Drugs.
United States market for Nucleic Acid and Oligonucleotide Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Nucleic Acid and Oligonucleotide Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Nucleic Acid and Oligonucleotide Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Nucleic Acid and Oligonucleotide Drugs players cover Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Nucleic Acid and Oligonucleotide Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
Antisense Oligonucleotides (ASO)
siRNA
mRNA
Segmentation by Application:
Neuromuscular Diseases
hATTR
COVID-19
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Antisense Oligonucleotides (ASO)
siRNA
mRNA
Segmentation by Application:
Neuromuscular Diseases
hATTR
COVID-19
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size 2019-2030
2.1.2 Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Nucleic Acid and Oligonucleotide Drugs by Country/Region, 2019, 2023 & 2030
2.2 Nucleic Acid and Oligonucleotide Drugs Segment by Type
2.2.1 Antisense Oligonucleotides (ASO)
2.2.2 siRNA
2.2.3 mRNA
2.3 Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size by Type
2.3.1 Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Nucleic Acid and Oligonucleotide Drugs Segment by Application
2.4.1 Neuromuscular Diseases
2.4.2 hATTR
2.4.3 COVID-19
2.4.4 Other
2.5 Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size by Application
2.5.1 Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size by Player
3.1 Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Nucleic Acid and Oligonucleotide Drugs Revenue by Player (2019-2024)
3.1.2 Global Nucleic Acid and Oligonucleotide Drugs Revenue 麻豆原创 Share by Player (2019-2024)
3.2 Global Nucleic Acid and Oligonucleotide Drugs Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Nucleic Acid and Oligonucleotide Drugs by Region
4.1 Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size by Region (2019-2024)
4.2 Global Nucleic Acid and Oligonucleotide Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size Growth (2019-2024)
4.4 APAC Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size Growth (2019-2024)
4.5 Europe Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size Growth (2019-2024)
4.6 Middle East & Africa Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size by Country (2019-2024)
5.2 Americas Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size by Type (2019-2024)
5.3 Americas Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size by Region (2019-2024)
6.2 APAC Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size by Type (2019-2024)
6.3 APAC Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size by Country (2019-2024)
7.2 Europe Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size by Type (2019-2024)
7.3 Europe Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Nucleic Acid and Oligonucleotide Drugs by Region (2019-2024)
8.2 Middle East & Africa Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Forecast
10.1 Global Nucleic Acid and Oligonucleotide Drugs Forecast by Region (2025-2030)
10.1.1 Global Nucleic Acid and Oligonucleotide Drugs Forecast by Region (2025-2030)
10.1.2 Americas Nucleic Acid and Oligonucleotide Drugs Forecast
10.1.3 APAC Nucleic Acid and Oligonucleotide Drugs Forecast
10.1.4 Europe Nucleic Acid and Oligonucleotide Drugs Forecast
10.1.5 Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Forecast
10.2 Americas Nucleic Acid and Oligonucleotide Drugs Forecast by Country (2025-2030)
10.2.1 United States 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
10.2.2 Canada 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
10.2.3 Mexico 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
10.2.4 Brazil 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
10.3 APAC Nucleic Acid and Oligonucleotide Drugs Forecast by Region (2025-2030)
10.3.1 China Nucleic Acid and Oligonucleotide Drugs 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
10.3.3 Korea 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
10.3.4 Southeast Asia 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
10.3.5 India 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
10.3.6 Australia 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
10.4 Europe Nucleic Acid and Oligonucleotide Drugs Forecast by Country (2025-2030)
10.4.1 Germany 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
10.4.2 France 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
10.4.3 UK 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
10.4.4 Italy 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
10.4.5 Russia 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
10.5 Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Forecast by Region (2025-2030)
10.5.1 Egypt 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
10.5.2 South Africa 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
10.5.3 Israel 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
10.5.4 Turkey 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
10.6 Global Nucleic Acid and Oligonucleotide Drugs Forecast by Type (2025-2030)
10.7 Global Nucleic Acid and Oligonucleotide Drugs Forecast by Application (2025-2030)
10.7.1 GCC Countries 麻豆原创 Nucleic Acid and Oligonucleotide Drugs Forecast
11 Key Players Analysis
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Information
11.1.2 Sarepta Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
11.1.3 Sarepta Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Sarepta Therapeutics Main Business Overview
11.1.5 Sarepta Therapeutics Latest Developments
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Information
11.2.2 Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Product Offered
11.2.3 Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Ionis Pharmaceuticals Main Business Overview
11.2.5 Ionis Pharmaceuticals Latest Developments
11.3 Alnylam
11.3.1 Alnylam Company Information
11.3.2 Alnylam Nucleic Acid and Oligonucleotide Drugs Product Offered
11.3.3 Alnylam Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Alnylam Main Business Overview
11.3.5 Alnylam Latest Developments
11.4 Biogen
11.4.1 Biogen Company Information
11.4.2 Biogen Nucleic Acid and Oligonucleotide Drugs Product Offered
11.4.3 Biogen Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Biogen Main Business Overview
11.4.5 Biogen Latest Developments
11.5 Nippon Shinyaku
11.5.1 Nippon Shinyaku Company Information
11.5.2 Nippon Shinyaku Nucleic Acid and Oligonucleotide Drugs Product Offered
11.5.3 Nippon Shinyaku Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Nippon Shinyaku Main Business Overview
11.5.5 Nippon Shinyaku Latest Developments
11.6 Sobi
11.6.1 Sobi Company Information
11.6.2 Sobi Nucleic Acid and Oligonucleotide Drugs Product Offered
11.6.3 Sobi Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Sobi Main Business Overview
11.6.5 Sobi Latest Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis Nucleic Acid and Oligonucleotide Drugs Product Offered
11.7.3 Novartis Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Novartis Main Business Overview
11.7.5 Novartis Latest Developments
11.8 BioNTech
11.8.1 BioNTech Company Information
11.8.2 BioNTech Nucleic Acid and Oligonucleotide Drugs Product Offered
11.8.3 BioNTech Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 BioNTech Main Business Overview
11.8.5 BioNTech Latest Developments
11.9 Pfizer
11.9.1 Pfizer Company Information
11.9.2 Pfizer Nucleic Acid and Oligonucleotide Drugs Product Offered
11.9.3 Pfizer Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Pfizer Main Business Overview
11.9.5 Pfizer Latest Developments
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Information
11.10.2 Moderna Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
11.10.3 Moderna Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Moderna Therapeutics Main Business Overview
11.10.5 Moderna Therapeutics Latest Developments
11.11 Jazz Pharmaceuticals
11.11.1 Jazz Pharmaceuticals Company Information
11.11.2 Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Product Offered
11.11.3 Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Jazz Pharmaceuticals Main Business Overview
11.11.5 Jazz Pharmaceuticals Latest Developments
11.12 CureVac
11.12.1 CureVac Company Information
11.12.2 CureVac Nucleic Acid and Oligonucleotide Drugs Product Offered
11.12.3 CureVac Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 CureVac Main Business Overview
11.12.5 CureVac Latest Developments
11.13 Regulus Therapeutics
11.13.1 Regulus Therapeutics Company Information
11.13.2 Regulus Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
11.13.3 Regulus Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Regulus Therapeutics Main Business Overview
11.13.5 Regulus Therapeutics Latest Developments
11.14 ProQR
11.14.1 ProQR Company Information
11.14.2 ProQR Nucleic Acid and Oligonucleotide Drugs Product Offered
11.14.3 ProQR Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.14.4 ProQR Main Business Overview
11.14.5 ProQR Latest Developments
11.15 Secarna
11.15.1 Secarna Company Information
11.15.2 Secarna Nucleic Acid and Oligonucleotide Drugs Product Offered
11.15.3 Secarna Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.15.4 Secarna Main Business Overview
11.15.5 Secarna Latest Developments
11.16 MiNA Therapeutics
11.16.1 MiNA Therapeutics Company Information
11.16.2 MiNA Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
11.16.3 MiNA Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.16.4 MiNA Therapeutics Main Business Overview
11.16.5 MiNA Therapeutics Latest Developments
11.17 Sylentis
11.17.1 Sylentis Company Information
11.17.2 Sylentis Nucleic Acid and Oligonucleotide Drugs Product Offered
11.17.3 Sylentis Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.17.4 Sylentis Main Business Overview
11.17.5 Sylentis Latest Developments
11.18 Arrowhead
11.18.1 Arrowhead Company Information
11.18.2 Arrowhead Nucleic Acid and Oligonucleotide Drugs Product Offered
11.18.3 Arrowhead Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.18.4 Arrowhead Main Business Overview
11.18.5 Arrowhead Latest Developments
11.19 Silence Therapeutics
11.19.1 Silence Therapeutics Company Information
11.19.2 Silence Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
11.19.3 Silence Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.19.4 Silence Therapeutics Main Business Overview
11.19.5 Silence Therapeutics Latest Developments
11.20 Dicerna
11.20.1 Dicerna Company Information
11.20.2 Dicerna Nucleic Acid and Oligonucleotide Drugs Product Offered
11.20.3 Dicerna Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.20.4 Dicerna Main Business Overview
11.20.5 Dicerna Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
